Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating a single clinical milestone inside Protara Therapeutics’ dense SEC disclosures can feel like hunting for a nucleotide in a genome. R&D expense tables, cash-runway projections, and FDA feedback notes are scattered across hundreds of pages—yet every line matters when a biotech’s value hinges on TARA-002 trial data or IV Choline Chloride approvals.
Stock Titan solves this problem in minutes. Our AI reads each new 10-K annual report and 10-Q quarterly earnings report, then explains how updated trial enrollment, orphan-drug incentives, and liquidity ratios affect valuation. Need the latest Protara Therapeutics insider trading Form 4 transactions? Real-time alerts flag executive stock moves as soon as EDGAR posts them, giving you instant visibility into management’s conviction.
Investors often ask, “Where can I find Protara Therapeutics’ Form 4 insider transactions in real time?” or “How do I interpret the company’s 8-K material events explained?”—you’ll find both here, distilled into plain language. Our coverage includes:
- 8-K events that summarize clinical hold notices or trial achievements
- Proxy statement executive compensation details tied to milestone bonuses
- Side-by-side views of cash burn trends across filings
- Protara Therapeutics earnings report filing analysis with quarter-over-quarter R&D variance
Every document—whether it’s a Protara Therapeutics annual report 10-K simplified or a sudden capital raise disclosed in an 8-K—streams to your dashboard the moment it hits EDGAR. Our AI-powered summaries transform complex biotech jargon into clear takeaways so you can focus on decisions, not page counts. Understanding Protara Therapeutics SEC documents with AI has never been easier.
Robinhood Markets, Inc. (HOOD) has filed a Form 144 indicating the intended sale of 250,000 common shares with an estimated aggregate market value of $23.6 million. The shares are slated to be sold through Morgan Stanley Smith Barney LLC on or about 07 July 2025 on the NASDAQ.
The filing lists 767,047,021 shares outstanding; the contemplated transaction therefore represents roughly 0.03 % of the float, suggesting limited dilution or trading-volume impact. The notice also discloses that 750,000 shares were sold on 01 July 2025 for $69.95 million under a Rule 10b5-1 plan attributed to Vladimir Tenev.
- The current sale plus the earlier disposal totals 1.0 million shares, generating about $93.5 million for the insider within a single week.
- The seller affirms awareness of no undisclosed adverse information, and reliance on a written 10b5-1 plan mitigates insider-trading risk.
While purely administrative and not a guarantee of execution, the filing signals continued insider selling activity. Investors often watch such patterns for sentiment clues, even when the share count is immaterial relative to the company’s overall capitalization.
Kanzhun Limited (BZ) – Form 144 filing overview
The notice discloses a proposed sale of 1,984,500 American Depositary Shares (ADS), each ADS representing two Class A ordinary shares. The filer intends to execute the transaction through UBS Financial Services, 11 Madison Ave., New York on or about 30 June 2025. Based on the filing’s stated market price, the block is valued at approximately US$35.9 million.
The issuer reports 913,310,598 ordinary shares outstanding; the proposed sale therefore represents roughly 0.22 % of the ordinary share count (≈0.43 % of the ADS float, given the 2-for-1 ratio). The securities were originally acquired on 20 May 2014 as “Founder Shares” in exchange for services rendered.
Recent insider activity: the same beneficial owner, Techwolf Limited, previously sold 1,921,500 ADS on 1 April 2025 for gross proceeds of US$32.17 million. Adding the new notice, total planned/ completed disposals within three months reach 3.91 million ADS (≈US$68 million).
Form 144 is a notice of intent; it does not guarantee execution, but it signals potential supply and possible insider sentiment. No new capital is issued, so there is no dilution; however, the sales could create an overhang and incremental selling pressure around the proposed date.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
What is the primary focus of Protara Therapeutics Inc?
How does Protara generate value in the biotech sector?
What is TARA-002 and which conditions does it target?
What distinguishes IV Choline Chloride in Protara's portfolio?
How does Protara address unmet medical needs?
What regulatory achievements have validated Protara’s approach?
How are Protara's clinical trials structured?
How does Protara differentiate itself from other biotech companies?
